Progress in clinical neurosciences: Advances in the management of low-grade gliomas

Canadian Journal of Neurological Sciences

Volumn 32, Issue 1, 2005, Pages 18-26

  Mason, Warren P ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE; LOMUSTINE; PROCARBAZINE; TEMOZOLOMIDE; VINCRISTINE;

ASTROCYTOMA; BRAIN BIOPSY; BRAIN RADIOGRAPHY; BRAIN SURGERY; BRAIN TOMOGRAPHY; CANCER CLASSIFICATION; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RISK; CANCER SURGERY; CANCER SURVIVAL; CHROMOSOME DELETION; CLINICAL FEATURE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; CONTROLLED CLINICAL TRIAL; DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; DISEASE COURSE; GLIOMA; HUMAN; IMMUNOHISTOCHEMISTRY; MALIGNANT TRANSFORMATION; MULTICENTER STUDY; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OLIGODENDROGLIA; OLIGODENDROGLIOMA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; RADIATION DOSE; RADIATION INJURY; RADIATION NECROSIS; RANDOMIZED CONTROLLED TRIAL; REVIEW; SEIZURE; SURVIVAL RATE; TREATMENT INDICATION;

EID: 14944348042     PISSN: 03171671     EISSN: None     Source Type: Journal    
DOI: 10.1017/S0317167100016838     Document Type: Review

References (74)

1. Shaw E, Arusell R, Scheithauer B, et al. Prospective randomized trial of low- versus high-dose radiation therapy in adults with supratentorial low-grade glioma: initial report of a North Central Cancer Group/Radiation therapy Oncology Group/Eastern Cooperative Oncology Group study. J Clin Oncol 2002; 20: 2267-2276.
2. Buatti J, Meeks S, Ryken T, Carlisle T. Low-grade gliomas: answering one question in a myriad of new questions. J Clin Oncol 2002; 20: 2223-2224.
3. Cairncross JG, Laperriere NJ. Low-grade gliomas: to treat or not to treat? Arch Neurol 1990; 47: 1139-1140.
4. Hart M, Petito C, Earle K. Mixed gliomas. Cancer 1974; 1: 134-140.
5. Leibel S, Sheline G, Wara W, Boldrey E, Neilson S. The role of radiation therapy in the treatment of astrocytomas. Cancer 1975; 35: 1551-1557.
6. Shaw E, Daumas-Duport C, Scheithauer B, et al. Radiation therapy in the management of low-grade supratentorial astrocytomas. J Neurosurg 1989; 70: 853-861.
7. Shaw E, Scheithauer B, O'Fallon J, Davis D. Mixed oligoastrocytomas: a survival and prognostic factor analysis. Neurosurgery 1994; 34: 577-582.
8. Philippon J, Clemenceau S, Fauchon F, Foncin J. Supratentorial low-grade astrocytomas in adults. Neurosurgery 1993; 32: 554-559.
9. McCormack B, Miller D, Budzilovich G, Voorhees G, Ransohoff J. Treatment and survival of low-grade astrocytoma in adults-1977-1988. Neurosurgery 1992; 31: 636-642.
10. Laws E, Taylor W, Clifton M, Okazaki H. Neurosurgical management of low-grade astrocytoma of the cerebral hemispheres. J Neurosurg 1984; 61: 665-673.
11. Burger P, Scheithauer B. Tumours of the Central Nervous System. Washington, DC. Armed Forces Institute of Pathology, 1994.
12. Daumas-Duport C, Scheithauer B, O'Fallon J, Kelly P. Grading of astrocytomas. A simple and reproducible method. Cancer 1988; 62: 2152-2165.
13. Russel D, Rubinstein L. Pathology of tumours of the central nervous system. Baltimore: Williams and Wilkins, 1989.
14. Whitton A, Bloom H. Low grade glioma of the cerebral hemispheres in adults: a retrospective analysis of 88 cases. Int J Radiat Oncol Biol Phys 1990; 18: 783-786.
15. Kraus J, Koopmann J, Kaskel P, et al. Shared allelic losses on chromosomes Ip and 19q suggest a common origin of oligodendroglioma and oligoastrocytoma. J Neuropathol Exp Neurol 1995; 54: 91-95.
16. Louis D. A molecular genetic model of astrocytoma histopathology. Brain Pathol 1997; 7: 755-764.
17. Louis DN. The p53 gene and protein in human brain tumours. J Neuropathol Exp Neurol 1994; 53: 11-21.
18. Louis D, von Deimling A, Chung R, et al. Comparative study of p53 gene and protein alterations in human astrocytomas. J Neuropathol Exp Neurol 1993; 52: 31-38.
19. Kitange G, Templeton K, Jenkins R. Recent advances in the molecular genetics of primary gliomas. Curr Opin Oncol 2003; 15: 197-203.
20. Cairncross JG, Ueki K, Zlatescu MC, et al. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 1998; 90: 1473-1479.
21. Reifenberger J, Reifenberger G, Liu L, et al. Molecular genetic analysis of oligodendroglial tumours shows preferential allelic deletions on 19q and 1p. Am J Pathol 1994; 145: 1175-1190.
22. von Deimling A, Louis D, von Ammon K, et al. Evidence for a tumour suppressor gene on chromosome 19q with human astrocytomas, oligodendrogliomas and mixed gliomas. Cancer Res 1992; 52: 4277-4279.
23. Buckner J, Gesme D Jr., O'Fallon JR, et al. Phase II trial of procarbazine, lomustine, and vincristine as initial therapy for patients with low-grade oligodendroglioma or oligoastrocytoma: efficacy and associations with chromosomal abnormalities. J Clin Oncol 2003; 21: 251-255.
24. Vertosick F, Selker R, Arena V. Survival of patients with well-differentiated astrocytomas diagnosed in the era of computed tomography. Neurosurgery 1991; 28: 496-501.
25. Soffietti R, Chio A, Giordana M, Vasario E. Prognostic factors in well-differentiated cerebral astrocytoma in the adult. Neurosurgery 1989; 24: 686-692.
26. Leighton C, Fisher B, Bauman G, et al. Supratentorial low-grade glioma in adults: an analysis of prognostic factors and timing of radiation. J Clin Oncol 1997; 15: 1294-1301.
27. Lee Y-Y, Tassel P, Bruner J, Moser R, Share J. Juvenile pilocytic astrocytomas: CT and MR characteristics. Am J Radiol 1989; 152: 1263-1270.
28. Brotchi J, Baleriaux D, Delecluse F. MRI and surgical treatment of low grade gliomas. IMBO/JIOC 1986; 211-215.
29. Kelly P, Daumas-Duport C, Scheithauer B, Kail B, Kispert D. Stereotactic histologic correlations of computed tomography- and magnetic resonance imaging-defined abnormalities in patients with glial neoplasms. Mayo Clin Proc 1987; 62: 450-459.
30. Stack J, Antoun N, Jenkins J, Metcalfe R, Isherwood I. Gadolinium-DTPA as a contrast agent in magnetic resonance imaging of the brain. Neuroradiology 1988; 30: 145-154.
31. Kelly P. Volumetric stereotactic surgical resection of intra-axial brain mass lesions. Mayo Clin Proc 1988; 63: 1186-1198.
32. Kilgore D, Breger R, Daniels D, et al. Cranial tissues: normal MR appearance after intravenous injection of Gd-DTPA. Radiology 1986; 160: 757-761.
33. Chamberlain M, Murovic J, Levin V. Absence of contrast enhancement on CT brain scans of patients with supratentorial malignant gliomas. Neurology 1988; 38: 1371-1374.
34. Kondziolka D, Lunsford L, Martinez A. Unreliability of contemporary neurodiagnostic imaging in evaluating suspected adult supratentorial (low-grade) astrocytoma. J Neurosurg 1993; 79: 533-536.
35. Kaschten B, Stevenaert A, Sadzot B, et al. Preoperative evaluation of 54 gliomas by PET with fluorine-18-fleurodeoxyglucose and/or carbon-11-methionine. J Nucl Med 1998; 39: 778-785.
36. Byrne T. Imaging of gliomas. Semin Oncol 1994; 21: 162-171.
37. Francavilla T, Miletich R, Dichiro G, et al. Positron emission tomography in the detection of malignant degeneration of low-grade gliomas. Neurosurgery 1989; 24: 1-5.
38. Hwang J, Egnaczyk G, Ballard E, et al. Proton MR spectroscopic characteristics of pediatric pilocytic astrocytomas. AJNR Am J Neuroradiol 1998; 19: 535-540.
39. Vigneron D, Bollen A, McDermott M, et al. Three-dimensional magnetic resonance spectroscopic imaging of histologically confirmed brain tumours. Magn Reson Imaging 2001; 19: 89-101.
40. Mundinger F, Weigel K. Considerations in the usage and results of curietherapy. In: Lunsford L, (Ed.) Modern Stereotactic Neurosurgery. Boston: Martinus Nijhoff, 1988: 245-258.
41. Karim A, Afra D, Cornu P, et al. Randomized trial on the efficacy of radiotherapy for cerebral low-grade glioma in the adult: European Organization for Research and Treatment of Cancer study 22845 with the Medical Research Council study BR04: an interim analysis. Int J Radiat Oncol Biol Phys 2002; 52: 316-324.
42. Shaw E, Scheithauer B, O'Fallon J. Supratentorial gliomas: a comparative study by grade and histologic type. J Neurooncol 1997; 31: 273-278.
43. Smith JS, Perry A, Borell TJ, Lee HK, et al. Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. J Clin Oncol 2000; 18: 636-645.
44. Kreth F, Faist M, Rossner R, Volk B, Ostertag C. Supratentorial World Health Organization Grade 2 astrocytomas and oligoastrocytomas. A new pattern of prognostic factors. Cancer 1997; 79: 370-379.
45. Scerrati M, Roselli R, Iacoangeli M, Pompucci A, Rossi G. Prognostic factors in low grade (WHO grade 11) gliomas of the cerebral hemispheres: the role of surgery. J Neurol Neurosurg Psychiatry 1996; 61: 291-296.
46. Janny P, Cure H, Mohr M, et al. Low grade supratentorial astrocytomas. Cancer 1994; 73: 1937-1945.
47. van Veelen M, Avezaat C, Kros J, van Putten W, Vecht C. Supratentorial low grade astrocytoma: prognostic factors, dedifferentiation, and the issue of early versus late surgery. J Neurol Neurosurg Psychiatry 1998; 64: 581-587.
48. Lote K, Egeland T, Hager B, et al. Survival, prognostic factors, and therapeutic efficacy in low-grade glioma: a retrospective study in 379 patients. J Clin Oncol 1997; 15: 3129-3140.
49. Karim A, Matt B, Hatlevoli R, et al. A randomized trial no dose-response in radiation therapy of low-grade cerebral glioma: European Organization for Research and Treatment of Cancer (EORTC) study 22844. Int J Radiat Oncol Biol Phys 1996; 36: 549-556.
50. Medbery C, Strauss K, Steinberg S, Cotelingam J, Fisher W. Low-grade astrocytomas: treatment results and prognostic variables. Int J Radiat Oncol Biol Phys 1988; 15: 837-841.
51. Pignatti F, van den Bent M, Curran D, et al. Prognostic factors for survival in adult patients with cerebral low-grade glioma. J Clin Oncol 2002; 20: 2076-2084.
52. Piepmeier J. Observations on the current treatment of low-grade astrocytic tumours of the cerebral hemispheres. J Neurosurg 1987; 67: 177-181.
53. Fadul C, Wood J, Thaler H, et al. Morbidity and mortality of craniotomy for excision of supratentorial gliomas. Neurology 1988; 38: 1374-1379.
54. Ciric I, Ammirati M, Vick N, Mikhael M. Supratentorial gliomas: surgical considerations and immediate postoperative results. Gross total resection versus partial resection. Neurosurgery 1987; 21: 21-26.
55. Salcman M, Scholtz H, Kaplan RS, Kulik S. Long-term survival in patients with malignant astrocytoma. Neurosurgery 1985; 34: 213-220.
56. Ammirati M, Vick N, Liao Y, Ciric I, Mikhael M. Effect of extent of surgical resection on survival and quality of life in patients with supratentorial glioblastomas and anaplastic astrocytoma. Neurosurgery 1987; 21: 201-206.
57. Vecht C, Avezaat C. Putten W, Eijkenboom W, Stefanko S. The influence of the extent of surgery on the neurological function and survival in malignant glioma. A retrospective analysis of 243 patients. J Neurol Neurosurg Psychiatry 1990; 53: 466-471.
58. Berger M, Deliganis A, Dobbins J, Keles G. The effect of extent of resection on recurrence in patients with low grade cerebral hemisphere gliomas. Cancer 1994; 74: 1784-1791.
59. Laws E, Taylor W, Bergstralh E, Okazaki H, Clifton M. The neurosurgical management of low-grade astrocytoma. Clin Neurosurg 1986; 61: 665-673.
60. Wara W. Radiation therapy for brain tumours. Cancer 1985; 55: 2291-2295.
61. Surma-Aho O, Niemela M, Vilkki J, et al. Adverse long-term effects of brain radiotherapy in adult low-grade glioma patients. Neurology 2001; 56: 1285-1290.
62. Taphoorn M, Schiphorst A, Snoek F, et al. Cognitive functions and quality of life in patients with low-grade gliomas: the impact of radiotherapy. Ann Neurol 1994; 36: 48-54.
63. Vigliani M-C, Sichez N, Poisson M, Delattre J-Y. A prospective study of cognitive functions following conventional radiotherapy for supratentorial gliomas in young adults: 4-year results. Int J Radiat Oncol Biol Phys 1996; 35: 527-533.
64. Roelcke U, von JA, Hausmann O, et al. Operated low grade astrocytomas: a long term PET study on the effect of radiotherapy. J Neurol Neurosurg Psychiatry 1999; 66: 644-647.
65. Bruehlmeier M, Roelcke U, Amsler B, et al. Effects of radiotherapy on brain glucose metabolism in patients operated on for low grade astrocytoma. J Neurol Neurosurg Psychiatry 1999; 66: 648-653.
66. Mason W. Chemotherapy for low-grade gliomas. FORUM Trends in Experimental and Clinical Medicine 2000; 10: 95-104.
67. Mason WP, Krol GS, DeAngelis LM. Low-grade oligodendroglioma responds to chemotherapy. Neurology 1996; 46: 203-207.
68. Soffietti R, Ruda R, Bradac GB, et al. PCV chemotherapy for recurrent oligodendrogliomas and oligoastrocytomas. Neurosurgery 1998; 43: 1066-1073.
69. Macdonald DR, Gaspar L, Cairncross J. Successful chemotherapy for newly diagnosed aggressive oligodendroglioma. Ann Neurol 1990; 27: 573-574.
70. Soffietti R. Chemotherapy with PCV for low grade nonenhancing oligodendrogliomas. Neurology 1999; 52 (Suppl. 2): A423.
71. Packer R, Lange B, Ater J, et al. Carboplatin and vincristine for recurrent and newly diagnosed low-erade gliomas of childhood. J Clin Oncol 1993; 11: 850-856.
72. Brada M. Viviers L, Abson C, et al. Phase II study of primary temozolomide chemotherapy in patients with WHO grade II gliomas. Ann Oncol 2003; 24: 1715-1721.
73. Quinn J, Reardon DA, Friedman AH, et al. Phase II trial of temozolomide in patients with progressive low-grade glioma. J Clin Oncol 2003; 21: 646-651.
74. Baumert B, Stupp R, van den Bent M, Mason W. Therapy with continuous temozolomide for low grade glioma, inclusion based on genetic classification: two study proposals of the EORTC (European Organization for Research and Treatment of Cancer). Neurooncology 2002; 4 (Suppl. 1): S7.